Severe Hypercholesterolemia Clinical Trial
| Verified date | March 2014 |
| Source | Otsuka Beijing Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Food and Drug Administration |
| Study type | Interventional |
To evaluate the effect of concomitant administration of Probucol and Cilostazol (based on Atorvastatin treatment) on the atherosclerosis related markers (including the thickness of the Achilles tendon) in severe hypercholesterolemia subject, through the observation of the thickness of the Achilles tendon, the thickness of mean carotid intima-media, anti-oxidation biomarkers and serum lipid profile.
| Status | Recruiting |
| Enrollment | 250 |
| Est. completion date | April 2017 |
| Est. primary completion date | April 2017 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: 1. The subject whose voluntary written informed consent is obtained for participation in this study; 2. 18=age=70; 3. The subject with low-density lipoprotein cholesterol (LDL-C) = 4.66 mmol/L (180 mg/dL) (the highest level either pre-treatment or on treatment); 4. The subject with ATT=9mm. Exclusion Criteria: 1. The subject with homozygous familial hyperlipidemia; 2. The subject who took Probucol within 6 months before the screening test; 3. The subject who took Cilostazol within 1 month before the screening test; 4. The subject who took Ezetimibe within 1 month before the screening test; 5. The subject who hoped to treat with Ezetimibe within this study period; 6. The subject being treated with Cyclosporine; 7. The subject with a history of hypersensitivity to Probucol and Cilostazol; 8. The subject with a triglyceride (TG) level greater than 4.52 mmol/L (400 mg/dL); 9. The subject with diabetes: HbA1c level greater than 8.4% (NGSP); 10. The subject with New York Heart Association (NYHA) classification: Class III and IV; 11. The subject with a QTc interval greater than 450 msec (male) or 470 msec (female); 12. The subject with serious ventricular arrythmias (frequent episodes of multifocal ventricular extrasystole); 13. The subject with atrial fibrillation (including paroxysmal atrial fibrillation); 14. The subject with congestive cardiac failure or unstable angina; 15. The subject with liver and renal functions that satisfy the following criteria within 28 days prior to start of the investigational medicinal product (IMP) administration. - AST =100 IU/L, ALT=100 IU/L - Serum creatinine =1.5 mg/dL (133 µmol/L) 16. The subject who are participating in another clinical trial; 17. Woman during pregnancy or potential pregnancy, and breastfeeding; 18. Women of childbearing potential who are not agree to use an appropriate method of contraception; 19. The subject who are not considered by the Investigators to be appropriate to participate in this study for any other reasons. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | Anzhen hospital | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Otsuka Beijing Research Institute |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT) | at Month 6, 12 and 24 | No | |
| Secondary | the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT) | at Month 12 and 24 | No | |
| Secondary | the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention) | 2 years | Yes | |
| Secondary | the effect of concomitant administration of Probucol and Cilostazol on biomarkers | 2 years | No | |
| Secondary | the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs) | 2 years | Yes |